<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PLETAL- cilostazol tablet </strong><br>Otsuka America Pharmaceutical, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use PLETAL safely and effectively.  See full prescribing information for PLETAL. <br><span class="Bold">PLETAL<span class="Sup">®</span> (cilostazol) tablets, for oral use</span>.<br>Initial U.S. Approval: 1999</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: CONTRAINDICATED IN <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">HEART FAILURE</span> PATIENTS </h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning.</span></h1>
<dl>
<dt>•</dt>
<dd><span class="Bold">PLETAL is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> of any severity. Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III. Several drugs with the pharmacologic effect have caused decreased survival compared to placebo patients with class III-IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</span></dd>
</dl>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: CONTRAINDICATED IN <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">HEART FAILURE</span> PATIENTS </h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning.</span></h1>
<dl>
<dt>•</dt>
<dd><span class="Bold">PLETAL is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> of any severity. Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III. Several drugs with the pharmacologic effect have caused decreased survival compared to placebo patients with class III-IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">PLETAL is a phosphodiesterase III inhibitor (PDE III inhibitor) indicated for the reduction of symptoms of <span class="product-label-link" type="condition" conceptid="442774" conceptname="Intermittent claudication">intermittent claudication</span>, as demonstrated by an increased walking distance <a href="#ID_a375f083-6425-4442-85bf-83d41637508a">(1)</a> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>•</dt>
<dd>The recommended dosage of PLETAL is 100 mg twice daily taken at least half an hour before or two hours after breakfast and dinner (<a href="#ID_3903652e-c289-44b0-b7e4-f5f03cc5e91f">2.1</a>)</dd>
<dt>•</dt>
<dd>Reduce the dose to 50 mg twice daily when coadministered with CYP3A4 inhibitors such as ketoconazole, itraconazole, erythromycin, and diltiazem, or CYP2C19 inhibitors such as ticlopidine, fluconazole, and omeprazole (<a href="#ID_5c96e74b-a47c-453b-80bb-9ff624fa9e16">2.2</a>)  </dd>
</dl></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Tablets: 50 mg and 100 mg (<a href="http://file:///C:%5CWindows%5CTEMP%5CPLETAL%20PLR_1.docx">3</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart failure</span> of any severity (<a href="#ID_153aa0d2-602a-4cea-af79-1ddfe4dbfd0b">4</a>) </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to cilostazol or any components of PLETAL (<a href="#ID_153aa0d2-602a-4cea-af79-1ddfe4dbfd0b">4</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Risks of <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachyarrhythmia</span> or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. Risks of exacerbations of <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span> or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> in patients with a history of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>  (<a href="#ID_1dda823d-2a7a-4640-addf-498c6437d7ce">5.1</a>)</dd>
<dt>•</dt>
<dd>Risks of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> or <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> progressing to <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>-monitor platelets and white blood cell counts (<a href="#ID_e2a102b6-19e7-47d5-bc30-128db057cbbe">5.2</a>)</dd>
<dt>•</dt>
<dd>Avoid use in patients with hemostatic disorders or active pathologic <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (<a href="#_5.3_Hemostatic_Disorders">5.3</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions greater than or equal to 2% and at least twice that for placebo in patients on 100 mg twice daily are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="437671" conceptname="Abnormal feces">abnormal stools</span>, and <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span> (<a href="#ID_20299aa4-8375-41fa-baea-25ae5646d4ce">6.1</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact </span><span class="Bold">Otsuka America Pharmaceutical, Inc. at 1-877-438-9927</span><span class="Bold"> or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</a></span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>
<span class="Italics">Strong and moderate CYP3A4 and CYP2C19 inhibitors:</span> Increase exposure to PLETAL. Reduce PLETAL dose (<a href="#ID_5c96e74b-a47c-453b-80bb-9ff624fa9e16">2.2</a>, <a href="#ID_493060d0-dbba-41ff-82fd-2c1601dada37">7.1</a>)</dd>
</dl></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 7/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: CONTRAINDICATED IN <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">HEART FAILURE</span> PATIENTS </a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE </a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION </a></h1>
<h2><a href="#section-2.1" class="toc">2.1	Recommended dosage  </a></h2>
<h2><a href="#section-2.2" class="toc">2.2	Dose Reduction with CYP3A4 and CYP2C19 Inhibitors   </a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS </a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS </a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS </a></h1>
<h2><a href="#section-5.1" class="toc">5.1	<span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span>  </a></h2>
<h2><a href="#section-5.2" class="toc">5.2	Hematologic Adverse Reactions   </a></h2>
<h2><a href="#section-5.3" class="toc">5.3	<span class="Bold">Hemostatic Disorders or Active Pathologic <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> </span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS </a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Trials Experience  </a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Postmarketing Experience  </a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS </a></h1>
<h2><a href="#section-7.1" class="toc">7.1	Inhibitors of CYP3A4 or CYP2C19 </a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS </a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy </a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers </a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use </a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use </a></h2>
<h2><a href="#section-8.5" class="toc">8.6	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>  </a></h2>
<h2><a href="#section-8.6" class="toc">8.7 	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>  </a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE </a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION </a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY </a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action </a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics </a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics </a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY </a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology </a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES </a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING </a></h1>
<h2><a href="#section-14.1" class="toc">16.1	How supplied  </a></h2>
<h2><a href="#section-14.2" class="toc">16.2	Storage and handling  </a></h2>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION </a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="ID_097ec92c-9cb7-4188-a214-6ebac5974f4b"></a><a name="section-1"></a><p></p>
<h1>WARNING: CONTRAINDICATED IN <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">HEART FAILURE</span> PATIENTS </h1>
<p class="First"><span class="Bold">PLETAL is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> of any severity. Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III. Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III-IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. (<a href="#ID_153aa0d2-602a-4cea-af79-1ddfe4dbfd0b">4</a>)</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_a375f083-6425-4442-85bf-83d41637508a"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE </h1>
<p class="First">PLETAL is indicated for the reduction of symptoms of <span class="product-label-link" type="condition" conceptid="442774" conceptname="Intermittent claudication">intermittent claudication</span>, as demonstrated by an increased walking distance.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_c35677cd-9a6c-42b1-9e3c-dff8aedcb24b"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3903652e-c289-44b0-b7e4-f5f03cc5e91f"></a><a name="section-2.1"></a><p></p>
<h2>2.1	Recommended dosage  </h2>
<p class="First">The recommended dosage of PLETAL is 100 mg twice daily taken at least half an hour before or two hours after breakfast and dinner. </p>
<p>Patients may respond as early as 2 to 4 weeks after the initiation of therapy, but treatment for up to 12 weeks may be needed before a beneficial effect is experienced. If symptoms are unimproved after 3 months, discontinue PLETAL.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5c96e74b-a47c-453b-80bb-9ff624fa9e16"></a><a name="section-2.2"></a><p></p>
<h2>2.2	Dose Reduction with CYP3A4 and CYP2C19 Inhibitors   </h2>
<p class="First">Reduce dose to 50 mg twice daily when coadministered with strong or moderate inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, erythromycin, and diltiazem) or inhibitors of CYP2C19 (e.g., ticlopidine, fluconazole, and omeprazole)<span class="Bold"><span class="Italics"></span></span>[<span class="Italics">see Drug Interactions (<a href="#ID_493060d0-dbba-41ff-82fd-2c1601dada37">7.1</a>)]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ID_a95be858-2868-488d-9345-184d9f4a3de5"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS </h1>
<p class="First">PLETAL is available as 50 mg triangular and 100 mg round, white debossed tablets<span class="Italics">.</span></p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_153aa0d2-602a-4cea-af79-1ddfe4dbfd0b"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS </h1>
<p class="First">PLETAL is contraindicated in patients with:</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart failure</span> of any severity: Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III. Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III-IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to cilostazol or any components of PLETAL (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>)</dd>
</dl>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_56fe69d8-93bb-4126-9081-302e4e5675e8"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1dda823d-2a7a-4640-addf-498c6437d7ce"></a><a name="section-5.1"></a><p></p>
<h2>5.1	<span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span>  </h2>
<p class="First">Cilostazol may induce <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachyarrhythmia</span> or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm. Patients with a history of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span> may be at risk for exacerbations of <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span> or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e2a102b6-19e7-47d5-bc30-128db057cbbe"></a><a name="section-5.2"></a><p></p>
<h2>5.2	Hematologic Adverse Reactions   </h2>
<p class="First">Cases of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> or <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> progressing to <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> when PLETAL was not immediately discontinued have been reported. <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span> is reversible on discontinuation of PLETAL. Monitor platelets and white blood cell counts periodically.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_32c8ed8f-1b79-4303-8a6e-5c4c2cdb5944"></a><a name="section-5.3"></a><p></p>
<h2>5.3	<span class="Bold">Hemostatic Disorders or Active Pathologic <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> </span>
</h2>
<p class="First">PLETAL inhibits platelet aggregation in a reversible manner. PLETAL has not been studied in patients with hemostatic disorders or active pathologic <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Avoid use of PLETAL in these patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_406d9716-ea9f-49fe-b0a1-6409a442633c"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS </h1>
<p class="First">The following adverse reactions are discussed in greater detail in<span class="Bold"></span>other sections of the labeling:</p>
<dl>
<dt>o</dt>
<dd>Patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span> [see <span class="Italics">Boxed Warning</span>]</dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span> [see <span class="Italics">Warnings and Precautions (<a href="#ID_1dda823d-2a7a-4640-addf-498c6437d7ce">5.1</a>)</span>]</dd>
<dt>o</dt>
<dd>Hematologic Adverse Reactions [see <span class="Italics">Warnings and Precautions (<a href="#ID_e2a102b6-19e7-47d5-bc30-128db057cbbe">5.2</a>)</span>]</dd>
<dt>o</dt>
<dd>Hemostatic Disorders or Active Pathologic <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> [see <span class="Italics">Warnings and Precautions</span> (<a href="#_5.3_Hemostatic_Disorders">5.3</a>)]</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_20299aa4-8375-41fa-baea-25ae5646d4ce"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Trials Experience  </h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>Adverse reactions were assessed in eight placebo-controlled clinical trials involving patients exposed to either 50 or 100 mg twice daily PLETAL (n=1301) or placebo (n=973), with a median treatment duration of 127 days for patients on PLETAL and 134 days for patients on placebo.</p>
<p>The most frequent adverse reaction resulting in discontinuation of therapy in more than 3% of patients treated with PLETAL was <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> [50 mg twice daily (1.3%), 100 mg twice daily (3.5%) and placebo (0.3%)]. Other frequent causes of discontinuation included <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, both 1.1% for PLETAL (all doses) versus 0.1% for placebo.</p>
<p>The most common adverse reactions, occurring in at least 2% of patients treated with PLETAL 50 or 100 mg twice daily, are shown in Table 1.</p>
<table width="527.25pt">
<caption><span>Table 1: Most Common Adverse Reactions in Patients on PLETAL (PLT) 50 or 100 mg Twice Daily (Incidence at least 2% and Occurring More Frequently (≥ 2%) in the 100 mg Twice Daily Group than on Placebo)</span></caption>
<col width="27%">
<col width="25%">
<col width="24%">
<col width="25%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Adverse Reactions<br></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Placebo (N=973)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">PLT 50 mg twice daily (N=303)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">PLT 100 mg twice daily (N=998)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">14%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">27%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">34%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">7%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">12%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">19%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="437671" conceptname="Abnormal feces">Abnormal stools</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">4%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">12%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">15%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitation</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">5%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">10%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">6%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">9%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">10%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">7%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">7%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">10%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">8%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">14%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">10%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">4%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">9%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">7%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">5%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">12%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">7%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">4%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">6%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">6%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">3%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">4%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">5%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">4%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">4%</p></td>
</tr>
</tbody>
</table>
<p>Less frequent clinical significant adverse reactions (less than 2%) that were experienced by patients treated with PLETAL 50 mg twice daily or 100 mg twice daily in the eight controlled clinical trials and that occurred at a frequency in the 100 mg twice daily group greater than in the placebo group are listed below. </p>
<p><span class="Italics">Body as a whole:</span> <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span></p>
<p><span class="Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4217221" conceptname="Nodal rhythm disorder">nodal arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4008580" conceptname="Ventricular bigeminy">ventricular extrasystoles</span>, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span></p>
<p><span class="Italics">Digestive: </span><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span></p>
<p><span class="Italics">Hematologic and Lymphatic</span>: <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span></p>
<p><span class="Italics">Metabolic and Nutritional:</span> increased creatinine, <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span></p>
<p><span class="Italics">Nervous:</span> <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span></p>
<p><span class="Italics">Respiratory: </span><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span></p>
<p><span class="Italics">Skin and Appendages:</span> <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span></p>
<p><span class="Italics">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="374025" conceptname="Retinal hemorrhage">retinal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span></p>
<p><span class="Italics">Urogenital:</span> <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f175b10a-04e4-4787-bc89-47a377d3a676"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Postmarketing Experience  </h2>
<p class="First">The following adverse reactions have been identified during post-approval use of PLETAL. Because these reactions are reported voluntarily from a population of an unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Italics">Blood and lymphatic system disorders:</span></p>
<p> <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">Aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">bleeding tendency</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span>:</span></p>
<p><span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de pointes</span> and QTc prolongation in patients with <span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">cardiac disorders</span> (e.g. complete <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>; and bradyarrythmia), <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>:</span></p>
<p><span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></p>
<p><span class="Italics">General disorders and administration site conditions:</span></p>
<p><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span></p>
<p><span class="Italics">Hepatobiliary disorders:</span></p>
<p>Hepatic dysfunction/<span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune system disorders</span>:</span></p>
<p><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span></p>
<p><span class="Italics">Investigations:</span></p>
<p>Blood glucose increased, <span class="product-label-link" type="condition" conceptid="4148593" conceptname="Blood urate raised">blood uric acid increased</span>, increase in BUN (blood urea increased), blood pressure increase</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span>:</span></p>
<p><span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">Intracranial hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">cerebral hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>, <span class="product-label-link" type="condition" conceptid="4176148" conceptname="Extradural intracranial hematoma">extradural hematoma</span> and <span class="product-label-link" type="condition" conceptid="4318408" conceptname="Subdural hematoma">subdural hematoma</span></p>
<p><span class="Italics">Renal and urinary disorders:</span></p>
<p><span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span></p>
<p><span class="Italics">Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span>:</span></p>
<p><span class="product-label-link" type="condition" conceptid="4301606" conceptname="Pulmonary hemorrhage">Pulmonary hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial pneumonia</span></p>
<p><span class="Italics">Skin and subcutaneous tissue disorders:</span></p>
<p><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span> subcutaneous, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin eruptions</span> including Stevens‑Johnson syndrome, skin <span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">drug eruption</span> (<span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">dermatitis medicamentosa</span>), <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span>:</span></p>
<p>Subacute stent <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_b6031422-cf55-448d-96d1-da681f23cf9a"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_493060d0-dbba-41ff-82fd-2c1601dada37"></a><a name="section-7.1"></a><p></p>
<h2>7.1	Inhibitors of CYP3A4 or CYP2C19 </h2>
<p class="First"><span class="Underline">Inhibitors of CYP3A4</span></p>
<p>Coadministration of strong (e.g., ketoconazole) and moderate (e.g., erythromycin, diltiazem and grapefruit juice) CYP3A4 inhibitors can increase exposure to PLETAL. Reduce PLETAL dose to 50 mg twice daily when coadministered with strong or moderate inhibitors of CYP3A4 <span class="Italics">[see Dosage and Administration (<a href="#ID_5c96e74b-a47c-453b-80bb-9ff624fa9e16">2.2</a>) and Clinical Pharmacology (<a href="#ID_0d9b1c9d-0ab9-4f93-8f33-fa0c9626802c">12.3</a>)].</span></p>
<p><span class="Underline">Inhibitors of CYP2C19</span></p>
<p>Coadministration with CYP2C19 inhibitors (e.g., omeprazole) increases systemic exposure of PLETAL active metabolites. Reduce PLETAL dose to 50 mg twice daily when coadministered with strong or moderate inhibitors of CYP2C19 <span class="Italics">[see Dosage and Administration (<a href="#ID_5c96e74b-a47c-453b-80bb-9ff624fa9e16">2.2</a>) and Clinical Pharmacology (<a href="#ID_0d9b1c9d-0ab9-4f93-8f33-fa0c9626802c">12.3</a>)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID_ad52684c-6489-4b89-8e77-0845da67e671"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS </h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_3cec8c1c-f294-4e10-8724-0ffa1b5af20c"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy </h2>
<p class="First"><span class="Underline">Teratogenic Effects</span></p>
<p><span class="Italics">Pregnancy Category C</span>. </p>
<p>PLETAL has been shown to be teratogenic in rats at doses that are greater than 5-times the human MRHD on a body surface area basis. There are no adequate and well-controlled studies in pregnant women. </p>
<p>In a rat developmental toxicity study, oral administration of 1000 mg cilostazol/kg/day was associated with decreased fetal weights, and increased incidences of cardiovascular, renal, and skeletal anomalies (ventricular septal, aortic arch and subclavian artery abnormalities, renal pelvic dilation, 14<span class="Sup">th</span> rib, and retarded ossification). At this dose, systemic exposure to unbound cilostazol in nonpregnant rats was about 5 times the exposure in humans given the MRHD. Increased incidences of <span class="product-label-link" type="condition" conceptid="434462" conceptname="Ventricular septal defect">ventricular septal defect</span> and retarded ossification were also noted at 150 mg/kg/day (5 times the MRHD on a systemic exposure basis). In a rabbit developmental toxicity study, an increased incidence of retardation of ossification of the sternum was seen at doses as low as 150 mg/kg/day. In nonpregnant rabbits given 150 mg/kg/day, exposure to unbound cilostazol was considerably lower than that seen in humans given the MRHD, and exposure to 3,4-dehydro-cilostazol was barely detectable.</p>
<p>When cilostazol was administered to rats during late pregnancy and lactation, an increased incidence of stillborn and decreased birth weights of offspring was seen at doses of 150 mg/kg/day (5 times the MRHD on a systemic exposure basis).</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_b0061521-9e25-40bb-8697-f0063d49d67c"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers </h2>
<p class="First">Transfer of cilostazol into milk has been reported in rats. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from PLETAL, discontinue nursing or discontinue PLETAL.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_f9a1182b-064e-407b-bfe0-3cadbfa3453f"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use </h2>
<p class="First">Safety and effectiveness of PLETAL in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_ea79e2f5-b2ab-4b28-8b66-4839fad1340c"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use </h2>
<p class="First">Of the total number of subjects (n = 2,274) in clinical studies of PLETAL, 56 percent were 65 years old and over, while 16 percent were 75 years old and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be excluded. Pharmacokinetic studies have not disclosed any age-related effects on the absorption, distribution, metabolism, and elimination of cilostazol and its metabolites.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f9fb0dd9-cf78-4262-bba0-6ac477cdb1bb"></a><a name="section-8.5"></a><p></p>
<h2>8.6	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>  </h2>
<p class="First">No dose adjustment is required in patients with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Patients with moderate or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> have not been studied in clinical trials and dosing recommendations cannot be provided <span class="Italics">[see Clinical Pharmacology (<a href="http://file:///C:/Users/laura10536/AppData/Local/i4i/Alice%20Windows%20Client/Open/laura10536/J9GLSAPP01/4553/PLETAL%20PLR_1.docx">12.3</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_84a26975-4a74-4e24-9cac-4b571a784fec"></a><a name="section-8.6"></a><p></p>
<h2>8.7 	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>  </h2>
<p class="First">No dose adjustment is required in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span><span class="Italics">. </span>Patients on dialysis have not been studied, but, it is unlikely that cilostazol can be removed efficiently by dialysis because of its high protein binding (95-98%) <span class="Italics">[see Clinical Pharmacology (<a href="#ID_0d9b1c9d-0ab9-4f93-8f33-fa0c9626802c">12.3</a>)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_c7ce8aed-3c75-4ad7-a53f-d581cb86d6b4"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE </h1>
<p class="First">Information on acute overdosage with PLETAL in humans is limited. The signs and symptoms of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdose</span> can be anticipated to be those of excessive pharmacologic effect: severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and possibly <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>. The patient should be carefully observed and given supportive treatment. Since cilostazol is highly protein-bound, it is unlikely that it can be efficiently removed by hemodialysis or peritoneal dialysis. The oral LD<span class="Sub">50</span> of cilostazol is greater than 5 g per kg in mice and rats and greater than 2 g per kg in dogs.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_01d46fb3-817f-4ef9-a48d-1955481c3a32"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION </h1>
<p class="First">PLETAL (cilostazol) is a quinolinone derivative that inhibits cellular phosphodiesterase (more specific for phosphodiesterase III). The empirical formula of cilostazol is C<span class="Sub">20</span>H<span class="Sub">27</span>N<span class="Sub">5</span>O<span class="Sub">2</span>, and its molecular weight is 369.46. Cilostazol is 6-[4-(1-cyclohexyl-1<span class="Italics">H</span>-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1<span class="Italics">H</span>)-quinolinone, CAS-73963-72-1. </p>
<p>The structural formula is:</p>
<div class="Figure">
<a name="id-1720578883"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=24d75b58-bafb-4440-b8d7-4f4079c08b0b&amp;name=pletal-chemstructure.jpg">
</div>
<p>Cilostazol occurs as white to off-white crystals or as a crystalline powder that is slightly soluble in methanol and ethanol, and is practically insoluble in water, 0.1 N HCl, and 0.1 N NaOH.</p>
<p>PLETAL (cilostazol) tablets for oral administration are available in 50 mg triangular and 100 mg round, white debossed tablets. Each tablet, in addition to the active ingredient, contains the following inactive ingredients: carboxymethylcellulose calcium, corn starch, hydroxypropyl methylcellulose 2910, magnesium stearate, and microcrystalline cellulose.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_a564570f-5248-43a5-9dc7-49a3a2bf9e8b"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY </h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_bc86b09a-4a20-409c-86a5-2f8281c64c5d"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action </h2>
<p class="First">PLETAL and several of its metabolites inhibit phosphodiesterase III activity and suppress cAMP degradation with a resultant increase in cAMP in platelets and blood vessels, leading to inhibition of platelet aggregation and vasodilation, respectively. </p>
<p>PLETAL reversibly inhibits platelet aggregation induced by a variety of stimuli, including thrombin, ADP, collagen, arachidonic acid, epinephrine, and shear stress.</p>
<p><span class="Italics">Cardiovascular effects:</span></p>
<p>Cilostazol affects both vascular beds and cardiovascular function. It produces heterogeneous dilation of vascular beds, with greater dilation in femoral beds than in vertebral, carotid or superior mesenteric arteries. Renal arteries were not responsive to the effects of cilostazol. </p>
<p>In dogs or cynomolgus monkeys, cilostazol increased heart rate, myocardial contractile force, and coronary blood flow as well as ventricular automaticity, as would be expected for a PDE III inhibitor. Left ventricular contractility was increased at doses required to inhibit platelet aggregation. A-V conduction was accelerated. In humans, <span class="product-label-link" type="condition" conceptid="444070" conceptname="Tachycardia">heart rate increased</span> in a dose-proportional manner by a mean of 5.1 and 7.4 beats per minute in patients treated with 50 and 100 mg twice daily, respectively.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="ID_f9d7fea8-fe29-40e9-98e2-dae422be52f5"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics </h2>
<p class="First">Cilostazol's effects on platelet aggregation were evaluated in both healthy subjects and in patients with stable symptoms of <span class="product-label-link" type="condition" conceptid="441874" conceptname="Cerebral thrombosis">cerebral thrombosis</span>, <span class="product-label-link" type="condition" conceptid="375557" conceptname="Cerebral embolism">cerebral embolism</span>, transient ischemic attack, or <span class="product-label-link" type="condition" conceptid="4278243" conceptname="Cerebral arteriosclerosis">cerebral arteriosclerosis</span> over a range of doses from 50 mg every day to 100 mg three times a day.  Cilostazol significantly inhibited platelet aggregation in a dose-dependent manner.  The effects were observed as early as 3 hours post-dose and lasted up to 12 hours following a single dose. Following chronic administration and withdrawal of cilostazol, the effects on platelet aggregation began to subside 48 hours after withdrawal and returned to baseline by 96 hours with no rebound effect.  A cilostazol dosage of 100 mg twice daily consistently inhibited platelet aggregation induced with arachidonic acid, collagen and adenosine diphosphate (ADP).  <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">Bleeding time</span> was not affected by cilostazol administration.</p>
<p>Effects on circulating plasma lipids have been examined in patients taking PLETAL. After 12 weeks, as compared to placebo, PLETAL 100 mg twice daily produced a reduction in triglycerides of 29.3 mg/dL (15%) and an increase in HDL-<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> of 4.0 mg/dL (≅ 10%).</p>
<p><span class="Underline">Drug Interactions</span></p>
<p><span class="Italics">Aspirin</span></p>
<p>Short-term (less than or equal to 4 days) coadministration of aspirin with PLETAL increased the inhibition of ADP-induced <span class="Italics">ex vivo</span> platelet aggregation by 22% - 37% when compared to either aspirin or PLETAL alone. Short-term (less than or equal to 4 days) coadministration of aspirin with PLETAL increased the inhibition of arachidonic acid-induced <span class="Italics">ex vivo</span> platelet aggregation by 20% compared to PLETAL alone and by 48% compared to aspirin alone. However, short-term coadministration of aspirin with PLETAL had no clinically significant impact on PT, aPTT, or <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> compared to aspirin alone. Effects of long-term coadministration in the general population are unknown.</p>
<p>In eight randomized, placebo-controlled, double-blind clinical trials, aspirin was coadministered with cilostazol to 201 patients. The most frequent doses and mean durations of aspirin therapy were 75-81 mg daily for 137 days (107 patients) and 325 mg daily for 54 days (85 patients). There was no apparent increase in frequency of hemorrhagic adverse effects in patients taking cilostazol and aspirin compared to patients taking placebo and equivalent doses of aspirin.</p>
<p><span class="Italics">Warfarin</span></p>
<p>Cilostazol did not inhibit the pharmacologic effects (PT, aPTT, <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span>, or platelet aggregation) of R- and S-warfarin after a single 25-mg dose of warfarin. The effect of concomitant multiple dosing of warfarin and PLETAL on the pharmacodynamics of both drugs is unknown. </p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_0d9b1c9d-0ab9-4f93-8f33-fa0c9626802c"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics </h2>
<p class="First">PLETAL is absorbed after oral administration. A high fat meal increases absorption, with an approximately 90% increase in C<span class="Sub">max</span> and a 25% increase in AUC. Absolute bioavailability is not known. Cilostazol is extensively metabolized by hepatic cytochrome P-450 enzymes, mainly 3A4, and, to a lesser extent, 2C19, with metabolites largely excreted in urine. Two metabolites are active, with one metabolite appearing to account for at least 50% of the pharmacologic (PDE III inhibition) activity after administration of PLETAL. </p>
<p>Pharmacokinetics are approximately dose proportional. Cilostazol and its active metabolites have apparent elimination half-lives of about 11-13 hours. Cilostazol and its active metabolites accumulate about 2-fold with chronic administration and reach steady state blood levels within a few days. The pharmacokinetics of cilostazol and its two major active metabolites were similar in healthy subjects and patients with <span class="product-label-link" type="condition" conceptid="442774" conceptname="Intermittent claudication">intermittent claudication</span> due to peripheral arterial disease (PAD). Figure 1 shows the mean plasma concentration-time profile at steady state after multiple dosing of PLETAL 100 mg twice daily.</p>
<p><span class="Bold">Figure 1: Mean Plasma Concentration-time Profile at Steady State after Multiple Dosing of PLETAL 100 mg Twice Daily</span></p>
<div class="Figure">
<a name="id-1095399680"></a><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=24d75b58-bafb-4440-b8d7-4f4079c08b0b&amp;name=pletal-figure1.jpg">
</div>
<p><span class="Underline">Distribution</span></p>
<p>Cilostazol is 95 - 98% protein bound, predominantly to albumin. The binding for 3,4-dehydro-cilostazol is 97.4% and for 4´-trans-hydroxy-cilostazol is 66%. Mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> did not affect protein binding. The free fraction of cilostazol was 27% higher in subjects with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> than in healthy volunteers. The displacement of cilostazol from plasma proteins by erythromycin, quinidine, warfarin, and omeprazole was not clinically significant.</p>
<p><span class="Underline">Metabolism</span></p>
<p>Cilostazol is eliminated predominantly by metabolism and subsequent urinary excretion of metabolites. Based on <span class="Italics">in vitro</span> studies, the primary isoenzymes involved in cilostazol’s metabolism are CYP3A4 and, to a lesser extent, CYP2C19. The enzyme responsible for metabolism of 3,4-dehydro-cilostazol, the most active of the metabolites, is unknown.</p>
<p>Following oral administration of 100 mg radiolabeled cilostazol, 56% of the total analytes in plasma was cilostazol, 15% was 3,4-dehydro-cilostazol (4-7 times as active as cilostazol), and 4% was 4´-trans-hydroxy-cilostazol (20% as active as cilostazol).</p>
<p><span class="Underline">Elimination</span></p>
<p>The primary route of elimination was via the urine (74%), with the remainder excreted in feces (20%). No measurable amount of unchanged cilostazol was excreted in the urine, and less than 2% of the dose was excreted as 3,4-dehydro-cilostazol. About 30% of the dose was excreted in urine as 4´-trans-hydroxy-cilostazol. The remainder was excreted as other metabolites, none of which exceeded 5%. There was no evidence of induction of hepatic microenzymes.</p>
<p><span class="Underline">Special Populations</span></p>
<p><span class="Italics">Age and Gender</span></p>
<p>The total and unbound oral clearances, adjusted for body weight, of cilostazol and its metabolites were not significantly different with respect to age (50 to 80 years) or gender.</p>
<p><span class="Italics">Smokers</span></p>
<p>Population pharmacokinetic analysis suggests that smoking decreased cilostazol exposure by about 20%.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>The pharmacokinetics of cilostazol and its metabolites were similar in subjects with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> as compared to healthy subjects.</p>
<p>Patients with moderate or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> have not been studied.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>The total pharmacologic activity of cilostazol and its metabolites was similar in subjects with mild to moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and in healthy subjects. Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> increases metabolite levels and alters protein binding of the parent. The expected pharmacologic activity, however, based on plasma concentrations and relative PDE III inhibiting potency of parent drug and metabolites, appeared little changed. Patients on dialysis have not been studied, but, it is unlikely that cilostazol can be removed efficiently by dialysis because of its high protein binding (95 - 98%).</p>
<p><span class="Underline">Drug Interactions</span></p>
<p>Cilostazol does not appear to inhibit CYP3A4<span class="Italics">.</span></p>
<p><span class="Italics">Warfarin</span></p>
<p>Cilostazol did not inhibit the metabolism of R- and S-warfarin after a single 25-mg dose of warfarin. </p>
<p><span class="Italics">Clopidogrel</span></p>
<p>Multiple doses of clopidogrel do not significantly increase steady state plasma concentrations of cilostazol.</p>
<p><span class="Italics">Strong Inhibitors of CYP3A4</span></p>
<p>A priming dose of ketoconazole 400 mg (a strong inhibitor of CYP3A4), was given one day prior to coadministration of single doses of ketoconazole 400 mg and cilostazol 100 mg. This regimen increased cilostazol C<span class="Sub">max</span> by 94% and AUC by 117%. Other strong inhibitors of CYP3A4, such as itraconazole, voriconazole, clarithromycin, ritonavir, saquinavir, and nefazodone would be expected to have a similar effect <span class="Italics">[see Dosage and Administration (<a href="#ID_5c96e74b-a47c-453b-80bb-9ff624fa9e16">2.2</a>), <span class="Underline">Drug Interactions </span>(<a href="#ID_493060d0-dbba-41ff-82fd-2c1601dada37">7.1</a>)]</span>.</p>
<p><span class="Italics">Moderate Inhibitors of CYP3A4</span></p>
<p><span class="Italics">Erythromycin and other macrolide antibiotics</span>: Erythromycin is a moderately strong inhibitor of CYP3A4. Coadministration of erythromycin 500 mg every 8h with a single dose of cilostazol 100 mg increased cilostazol C<span class="Sub">max</span> by 47% and AUC by 73%. Inhibition of cilostazol metabolism by erythromycin increased the AUC of 4´-trans-hydroxy-cilostazol by 141% <span class="Italics">[see Dosage and Administration (<a href="#ID_5c96e74b-a47c-453b-80bb-9ff624fa9e16">2.2</a></span>)<span class="Italics">]</span>.</p>
<p><span class="Italics">Diltiazem</span>: </p>
<p>Diltiazem 180 mg decreased the clearance of cilostazol by ~30%. Cilostazol C<span class="Sub">max</span> increased ~30% and AUC increased ~40% <span class="Italics">[see</span><span class="Italics">Dosage and Administration (<a href="#ID_5c96e74b-a47c-453b-80bb-9ff624fa9e16">2.2</a></span>)<span class="Italics">]</span>.</p>
<p><span class="Italics">Grapefruit Juice</span>: </p>
<p>Grapefruit juice increased the C<span class="Sub">max</span> of cilostazol by ~50%, but had no effect on AUC.</p>
<p><span class="Italics">Inhibitors of CYP2C19</span></p>
<p><span class="Italics">Omeprazole: </span>Coadministration of omeprazole did not significantly affect the metabolism of cilostazol, but the systemic exposure to 3,4-dehydro-cilostazol was increased by 69%, probably the result of omeprazole’s potent inhibition of CYP2C19 <span class="Italics">[</span>see <span class="Italics">Dosage and Administration (<a href="#ID_5c96e74b-a47c-453b-80bb-9ff624fa9e16">2.2</a></span>)<span class="Italics">]</span>.</p>
<p><span class="Italics">Quinidine</span></p>
<p>Concomitant administration of quinidine with a single dose of cilostazol 100 mg did not alter cilostazol pharmacokinetics.</p>
<p><span class="Italics">Lovastatin</span></p>
<p>The concomitant administration of lovastatin with cilostazol decreases cilostazol C<span class="Sub">ss, max </span>and AUC<span class="Sub">τ</span> by 15%. There is also a decrease, although nonsignificant, in cilostazol metabolite concentrations. Coadministration of cilostazol with lovastatin increases lovastatin and ß-hydroxylovastatin AUC approximately 70% and is not expected to be clinically significant.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="ID_78a2295b-da52-4b2a-bc1e-cd343fa25398"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY </h1>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_d119304d-dd5b-4ca1-a719-35c913794c7f"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </h2>
<p class="First">Dietary administration of cilostazol to male and female rats and mice for up to 104 weeks, at doses up to 500 mg/kg/day in rats and 1000 mg/kg/day in mice, revealed no evidence of carcinogenic potential. The maximum doses administered in both rat and mouse studies were, on a systemic exposure basis, less than the human exposure at the MRHD of the drug. Cilostazol tested negative in bacterial gene mutation, bacterial DNA repair, mammalian cell gene mutation, and mouse <span class="Italics">in vivo</span> bone marrow chromosomal aberration assays. It was, however, associated with a significant increase in chromosomal aberrations in the <span class="Italics">in vitro</span> Chinese Hamster Ovary Cell assay. </p>
<p>Cilostazol did not affect fertility or mating performance of male and female rats at doses as high as 1000 mg/kg/day. At this dose, systemic exposures (AUCs) to unbound cilostazol were less than 1.5 times in males, and about 5 times in females, the exposure in humans at the MRHD.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="ID_5309f31a-09d1-4862-860a-5ebce2fa9ad6"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology </h2>
<p class="First">Repeated oral administration of cilostazol to dogs (30 or more mg/kg/day for 52 weeks, 150 or more mg/kg/day for 13 weeks, and 450 mg/kg/day for 2 weeks), produced cardiovascular lesions that included endocardial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, hemosiderin deposition and <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span> in the left ventricle, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> in the right atrial wall, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> and <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> of the smooth muscle in the wall of the coronary artery, intimal thickening of the coronary artery, and coronary <span class="product-label-link" type="condition" conceptid="314659" conceptname="Arteritis">arteritis</span> and periarteritis. At the lowest dose associated with cardiovascular lesions in the 52-week study, systemic exposure (AUC) to unbound cilostazol was less than that seen in humans at the maximum recommended human dose (MRHD) of 100 mg twice daily. Similar lesions have been reported in dogs following the administration of other positive inotropic agents (including PDE III inhibitors) and/or vasodilating agents. No cardiovascular lesions were seen in rats following 5 or 13 weeks of administration of cilostazol at doses up to 1500 mg/kg/day. At this dose, systemic exposures (AUCs) to unbound cilostazol were only about 1.5 and 5 times (male and female rats, respectively) the exposure seen in humans at the MRHD. Cardiovascular lesions were also not seen in rats following 52 weeks of administration of cilostazol at doses up to 150 mg/kg/day. At this dose, systemic exposures (AUCs) to unbound cilostazol were about 0.5 and 5 times (male and female rats, respectively) the exposure in humans at the MRHD. In female rats, cilostazol AUCs were similar at 150 and 1500 mg/kg/day. Cardiovascular lesions were also not observed in monkeys after oral administration of cilostazol for 13 weeks at doses up to 1800 mg/kg/day. While this dose of cilostazol produced pharmacologic effects in monkeys, plasma cilostazol levels were less than those seen in humans given the MRHD, and those seen in dogs given doses associated with cardiovascular lesions.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_799f6727-8978-401a-9b32-37f53801e896"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES </h1>
<p class="First">The ability of PLETAL to improve walking distance in patients with stable <span class="product-label-link" type="condition" conceptid="442774" conceptname="Intermittent claudication">intermittent claudication</span> was studied in eight, randomized, placebo-controlled, double-blind trials of 12 to 24 weeks’ duration involving 2,274 patients using dosages of 50 mg twice daily (n=303), 100 mg twice daily (n=998), and placebo (n=973). Efficacy was determined primarily by the change in maximal walking distance from baseline (compared to change on placebo) on one of several standardized exercise treadmill tests.</p>
<p>Compared to patients treated with placebo, patients treated with PLETAL 50 or 100 mg twice daily experienced statistically significant improvements in walking distances both for the distance before the onset of <span class="product-label-link" type="condition" conceptid="442774" conceptname="Intermittent claudication">claudication</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and the distance before exercise-limiting symptoms supervened (maximal walking distance). The effect of PLETAL on walking distance was seen as early as the first on-therapy observation point of two or four weeks.</p>
<p>Figure 2 depicts the percent mean improvement in maximal walking distance, at study end for each of the eight studies.</p>
<p><span class="Bold">Figure 2: Percent Mean Improvement in Maximal Walking Distance at Study End for the Eight Randomized, Double-Blind, Placebo-Controlled Clinical Trials</span></p>
<div class="Figure">
<a name="id30773799"></a><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=24d75b58-bafb-4440-b8d7-4f4079c08b0b&amp;name=pletal-figure2.jpg">
</div>
<p>Across the eight clinical trials, the range of improvement in maximal walking distance in patients treated with PLETAL 100 mg twice daily, expressed as the change from baseline, was 28% to 100%.</p>
<p>The corresponding changes in the placebo group were –10% to 41%.</p>
<p>The Walking Impairment Questionnaire, which was administered in six of the eight clinical trials, assesses the impact of a therapeutic intervention on walking ability. In a pooled analysis of the six trials, patients treated with either PLETAL 100 mg twice daily or 50 mg twice daily reported improvements in their walking speed and walking distance as compared to placebo. Improvements in walking performance were seen in the various subpopulations evaluated, including those defined by gender, smoking status, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, duration of peripheral artery disease, age, and concomitant use of beta blockers or calcium channel blockers. PLETAL<span class="Bold"></span>has not been studied in patients with rapidly progressing <span class="product-label-link" type="condition" conceptid="442774" conceptname="Intermittent claudication">claudication</span> or in patients with <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">leg pain</span> at rest, ischemic leg <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>, or <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">gangrene</span>. Its long-term effects on limb preservation and hospitalization have not been evaluated.</p>
<p>A randomized, double-blind, placebo-controlled Phase IV study was conducted to assess the long-term effects of cilostazol, with respect to mortality and safety, in 1,439 patients with <span class="product-label-link" type="condition" conceptid="442774" conceptname="Intermittent claudication">intermittent claudication</span> and no <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. The trial stopped early due to enrollment difficulties and a lower than expected overall <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> rate. With respect to mortality, the observed 36-month Kaplan-Meier event rate for <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> on study drug with a median time on study drug of 18 months was 5.6% (95% CI of 2.8 to 8.4 %) on cilostazol and 6.8% (95% CI of 1.9  to 11.5 %) on placebo.  These data appear to be sufficient to exclude a 75% increase in the risk of mortality on cilostazol, which was the <span class="Italics">a priori</span> study hypothesis.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_a3a8061f-3ba7-4c93-b386-024a2c721c70"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f71dd523-51f2-45f5-9164-7d9761c67782"></a><a name="section-14.1"></a><p></p>
<h2>16.1	How supplied  </h2>
<p class="First">PLETAL is supplied as 50 mg and 100 mg tablets. </p>
<p>The 50 mg tablets are white, triangular, debossed with PLETAL 50, and provided in bottles of 60 tablets (NDC 59148-003-16).</p>
<p>The 100 mg tablets are white, round, debossed with PLETAL 100, and provided in bottles of 60 tablets (NDC 59148-002-16).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_09a5a8ea-2444-4e3f-9500-c294bde1520c"></a><a name="section-14.2"></a><p></p>
<h2>16.2	Storage and handling  </h2>
<p class="First">Store PLETAL tablets at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [See USP Controlled Room Temperature].</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_59d46d5e-ef4a-41ba-bd30-be5c0350c357"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION </h1>
<p class="First">Advise the patient to read the FDA-approved patient labeling (Patient Information)</p>
<p>Advise the patient:</p>
<dl>
<dt>•</dt>
<dd>to take PLETAL at least one-half hour before or two hours after food. </dd>
<dt>•</dt>
<dd>to discuss with their doctor before taking any CYP3A4 or CYP2C19 inhibitors (e.g., omeprazole).</dd>
<dt>•</dt>
<dd>that the beneficial effects of PLETAL on the symptoms of <span class="product-label-link" type="condition" conceptid="442774" conceptname="Intermittent claudication">intermittent claudication</span> may not be immediate. Although the patient may experience benefit in 2 to 4 weeks after initiation of therapy, treatment for up to 12 weeks may be required before a beneficial effect is experienced. Discontinue PLETAL if symptoms do not improve after 3 months.  </dd>
</dl>
<p>Manufactured for</p>
<p><span class="Bold">OTSUKA AMERICA PHARMACEUTICAL, INC.</span></p>
<p>Rockville, MD 20850</p>
<p>Manufactured by</p>
<p><span class="Bold">OTSUKA PHARMACEUTICAL CO., LTD.</span></p>
<p>Tokushima 771-0182, Japan</p>
<div class="Figure">
<a name="id1617868222"></a><img alt="Otsuka Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=24d75b58-bafb-4440-b8d7-4f4079c08b0b&amp;name=pletal-logo.jpg">
</div>
<p>July 2015</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="ID_d1104f77-3e79-4f3c-b9d3-fb0a83ff7e61"></a><a name="section-16"></a><p></p>
<h1>PATIENT INFORMATION</h1>
<p class="First"><span class="Bold">PLETAL<span class="Sup">®</span> (PLAY-tal)</span></p>
<p><span class="Bold">(cilostazol)</span></p>
<p><span class="Bold">Tablets, for oral use</span></p>
<p>Read this Patient Information leaflet before you start taking PLETAL and each time you get a refill. There may be new information. This information does not take the place of talking to your doctor about your medical condition or your treatment.  </p>
<p><span class="Bold">What is the most important information I should know about PLETAL?</span></p>
<p><span class="Bold">PLETAL can cause serious side effects:</span></p>
<p>•	PLETAL (cilostazol) stops a protein called phosphodiesterase III from working. Other similar drugs which affect this protein may cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> if you already have heart problems, called class 3 to 4 (III-IV) <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.  <span class="Bold">	Do not</span>	 take PLETAL if you have <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> of any kind.</p>
<p><span class="Bold">What is PLETAL?</span></p>
<p>PLETAL is a prescription medicine used to reduce the symptoms of <span class="product-label-link" type="condition" conceptid="442774" conceptname="Intermittent claudication">intermittent claudication</span> and can increase your ability to walk further distances.</p>
<p>It is not known if PLETAL is safe and effective for use in children. </p>
<p><span class="Bold">How does PLETAL work?</span></p>
<p>Improvement in symptoms may occur as soon as 2 weeks, but could take up to 12 weeks.  </p>
<p><span class="Bold">Who should not take PLETAL?</span></p>
<p><span class="Bold">Do not take PLETAL if you:</span></p>
<p>•	have heart problems (<span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>)  </p>
<p>•	are allergic to cilostazol or any of the ingredients in PLETAL. See the end of this leaflet for a complete list of ingredients in PLETAL.</p>
<p>Tell your doctor before taking this medicine if you have any of these conditions.</p>
<p><span class="Bold">What should I tell my doctor before taking PLETAL?</span></p>
<p><span class="Bold">Before you take PLETAL, tell your doctor if you:</span></p>
<p>•	drink grapefruit juice. Taking PLETAL and drinking grapefruit juice can increase the amount of PLETAL causing side effects. </p>
<p>•	have any other medical conditions</p>
<p>•	are pregnant or planning to become pregnant. It is not known if PLETAL will harm your unborn baby.</p>
<p>•	are breastfeeding or planning to breastfeed. It is not known if PLETAL passes into your breast milk.  You and your doctor should decide if you will take PLETAL or breastfeed. You should not do both.</p>
<p><span class="Bold">Tell your doctor about all the medicines you take,</span> including prescription and over-the-counter medicines, vitamins and herbal supplements.</p>
<p>Ask your doctor for a list of these medicines if you are not sure. You can ask your pharmacist for a list of medicines that interact with PLETAL. Know the medicines you take. Keep a list of them to show to your doctor and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take PLETAL?</span></p>
<p>•	Take PLETAL exactly as your doctor tells you to take it.</p>
<p>•	Your doctor will tell you how much PLETAL to take and when to take it.</p>
<p>•	Your doctor may change your dose if needed.</p>
<p>•	Take PLETAL <span class="Bold">	30 minutes before</span>	 you eat <span class="Bold">	or 2 hours after</span>	 you eat.</p>
<p><span class="Bold">What are the possible side effects of PLETAL?</span></p>
<p><span class="Bold">PLETAL may cause serious side effects, including:</span></p>
<p>•<span class="Bold">	heart problems.</span>	 Taking PLETAL may cause you to have heart problems, including a fast heart beat, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, irregular heartbeat, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span>. </p>
<p>•	See “What is the most important information I should know about PLETAL??</p>
<p>•<span class="Bold">	severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> (<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>).</span>	 Call your doctor or go to the nearest emergency room right away if you have any of the following signs or symptoms of a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>:</p>
<p>o	<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span></p>
<p>o	<span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face, lips, mouth, or tongue</p>
<p>o	trouble breathing or <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span></p>
<p>o	<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></p>
<p><span class="Bold">•	changes in your blood cell counts (<span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> or <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>). </span>Your doctor should do blood tests to check your blood cell counts while you take PLETAL. </p>
<p><span class="Bold">The most common side effects of PLETAL include:</span></p>
<p>•	<span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></p>
<p>•	<span class="product-label-link" type="condition" conceptid="437671" conceptname="Abnormal feces">abnormal stools</span></p>
<p>•	<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></p>
<p></p>
<p>Tell your doctor if you have any side effect that bothers you or does not go away. These are not all the possible side effects of PLETAL. For more information, ask your doctor or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store PLETAL?</span></p>
<p>Store PLETAL at room temperature between 68°F to 77°F (20°C to 25°C).</p>
<p><span class="Bold">Keep PLETAL and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about the safe and effective use of PLETAL.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use PLETAL for a condition for which it was not prescribed. Do not give PLETAL to other people, even if they have the same symptoms that you have. It may harm them. </p>
<p>This Patient Information summarizes the most important information about PLETAL. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about PLETAL that is written for health professionals.</p>
<p>For more information, go to www.otsuka-us.com or call 1-800-441-6763.</p>
<p><span class="Bold">What are the ingredients in PLETAL?</span></p>
<p><span class="Bold">Active ingredient:</span> cilostazol</p>
<p><span class="Bold">Inactive ingredients:</span> carboxymethylcellulose calcium, corn starch, hydroxypropyl methylcellulose 2910, magnesium stearate, microcrystalline cellulose</p>
<p><span class="Bold">This Patient Information has been approved by the U.S. Food and Drug Administration.</span></p>
<p></p>
<p>Manufactured for</p>
<p><span class="Bold">OTSUKA AMERICA PHARMACEUTICAL, INC.</span></p>
<p>Rockville, MD 20850</p>
<p>Manufactured by</p>
<p><span class="Bold">OTSUKA PHARMACEUTICAL CO., LTD.</span></p>
<p>Tokushima 771-0182, Japan</p>
<p></p>
<p> Revised: July/2015</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_edc097b0-c662-48c0-9a64-22a11aa1a165"></a><a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL 50 mg Tablet Bottle Label </h1>
<p class="First">NDC 59148-003-16</p>
<p><span class="Italics">Tablets</span><br><span class="Bold"><span class="Italics">PLETAL</span></span><span class="Sup">®</span><br><span class="Italics">(cilostazol)</span></p>
<p><span class="Bold">50mg</span></p>
<p><span class="Bold">OTSUKA AMERICA</span><br><span class="Bold">PHARMACEUTICAL, INC.</span></p>
<p><span class="Bold">60 TABLETS</span></p>
<div class="Figure">
<a name="id-805465646"></a><img alt="Pletal 50 mg Tablet Bottle" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=24d75b58-bafb-4440-b8d7-4f4079c08b0b&amp;name=pletal-50mg-tablet-bottle-label.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_aa9a1ac9-5273-44ea-b048-26e4693428b3"></a><a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 100 mg Tablet Bottle Label  </h1>
<p class="First">NDC 59148-002-16</p>
<p><span class="Italics">Tablets</span><br><span class="Bold"><span class="Italics">PLETAL</span></span><span class="Sup">®</span><br><span class="Italics">(cilostazol)</span></p>
<p><span class="Bold">100 mg</span></p>
<p><span class="Bold">OTSUKA AMERICA</span><br><span class="Bold">PHARMACEUTICAL, INC.</span></p>
<p><span class="Bold">60 TABLETS</span></p>
<div class="Figure">
<a name="id427703036"></a><img alt="PRINCIPAL DISPLAY PANEL - 100 mg Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=24d75b58-bafb-4440-b8d7-4f4079c08b0b&amp;name=pletal-100mg-tablet-bottle-label.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PLETAL 		
					</strong><br><span class="contentTableReg">cilostazol tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:59148-003</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>cilostazol</strong> (cilostazol) </td>
<td class="formItem">cilostazol</td>
<td class="formItem">50 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>carboxymethylcellulose calcium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>starch, corn</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>carboxymethylcellulose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">TRIANGLE</td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">PLETAL;50</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:59148-003-16</td>
<td class="formItem">60  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020863</td>
<td class="formItem">01/15/1999</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PLETAL 		
					</strong><br><span class="contentTableReg">cilostazol tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:59148-002</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>cilostazol</strong> (cilostazol) </td>
<td class="formItem">cilostazol</td>
<td class="formItem">100 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>carboxymethylcellulose calcium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>starch, corn</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>carboxymethylcellulose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">PLETAL;100</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:59148-002-16</td>
<td class="formItem">60  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020863</td>
<td class="formItem">01/15/1999</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Otsuka America Pharmaceutical, Inc.
							(008314390)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 7/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>dc9b7159-7027-4287-bed8-983aba53df7d</div>
<div>Set id: 24d75b58-bafb-4440-b8d7-4f4079c08b0b</div>
<div>Version: 8</div>
<div>Effective Time: 20150730</div>
</div>
</div> <div class="DistributorName">Otsuka America Pharmaceutical, Inc.</div></p>
</body></html>
